This Week in Cardiology Mar 13 2026 This Week in Cardiology
Mar 13, 2026
Discussion of beta-blocker versus calcium channel blocker effects in non-obstructive hypertrophic cardiomyopathy. A direct apixaban versus rivaroxaban randomized trial focusing on bleeding risk. Comparison of diltiazem and metoprolol when combined with direct oral anticoagulants. Evaluation of smartwatch accuracy for atrial fibrillation detection and post-ablation monitoring.
AI Snips
Chapters
Transcript
Episode notes
Beta Blockers Reduce Exercise Capacity In Nonobstructive HCM
- Beta blockers worsen exercise capacity in non-obstructive hypertrophic cardiomyopathy (HCM).
- Crossover RCT (32 patients) showed basoprolol reduced peak VO2 versus verapamil and placebo and increased BNP and worsened KCCQ scores.
Mandrola's 80 Kilometer Bike Ride In Ohus Denmark
- John Mandrola recalls visiting Ohus, Denmark and biking 80 kilometers with young people which left a vivid impression.
- He uses this memory when introducing the Danish trial team that performed the HCM crossover RCT.
Avoid Routine Beta Blockers In Nonobstructive HCM
- Avoid routine beta-blocker use in non-obstructive HCM unless there is a clear indication like rapid atrial fibrillation.
- Use verapamil over beta-blocker if symptoms (palpitations or exertional dyspnea) require therapy, per trial findings.